Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
批准号:
10174848
负责人:
Jasvinder A Singh
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2022-01-31
关键词:
AccountingActivities of Daily LivingAdmixtureAge-YearsArthritisDataDegenerative polyarthritisDiagnosisDiseaseDisease ProgressionEthnic groupFailureGeneral PopulationGeneticGoalsHabilitationHealth Care CostsHealthcare SystemsHeritabilityHeterogeneityHip region structureHospitalizationIncidenceIndividualKneeLife StyleMediatingMeta-AnalysisOperative Surgical ProceduresOutcomePainParticipantPhenotypePrevalencePublic HealthRecording of previous eventsRecoveryRehabilitation therapyReplacement ArthroplastyResourcesSurveysTestingTraumatic ArthropathyTreatment CostVariantVeteransbiobankcohortcommon symptomcomorbiditydisabilityend stage diseaseexperiencegenetic informationgenetic predictorsgenetic variantgenome wide association studyhealth care service utilizationhealth related quality of lifehip replacement arthroplastyimproved mobilityknee replacement arthroplastypatient orientedprimary outcomeprognosticprogramsrecruitrehabilitation strategyresponsesecondary analysissecondary outcomesuccesstargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The societal and patient-centered impacts of end-stage osteoarthritis (OA) among Veterans – including a
significant proportion suffering from post-traumatic arthritis – are profound: (i) VA healthcare costs for
treatment exceed $880 million annually; (ii) ~30% of Veterans in the VA healthcare system have OA, which is
a significantly higher rate than the general population; (iii) each year, 10,000 Veterans with end-stage arthritis
undergo total hip (n~3500) or knee (n~6500) arthroplasty (THA/TKA) and subsequent rehabilitation; (iv)
Veterans who undergo THA/TKA experience profound deficits in health-related quality of life (HRQL), severe
functional limitations in activities of daily living (ADL), increased healthcare utilization, and higher incidence of
comorbidities and hospitalization; and (v) incidence of moderate-severe functional limitations 2-5 years post-
surgery is 30-35% post-THA and 46-50% post-TKA despite prescribed rehabilitation. OA has a strong genetic
component with heritability estimates >30%. Pain is the most common symptom, contributing to disability and
decreased HRQL. Major phenotypic predictors of post-THA/TKA mobility limitation and pain have been
identifed. However, genetic predictors of both the progression of OA and success of THA/TKA recovery are as
yet unknown. Such discovery would fuel progress toward precision pre-habilitation and post-surgical
rehabilitation among Veterans. We seek to leverage the rich MVP resource to test the overarching
hypothesis that genetic variants explain a meaningful proportion of OA prevalence, progression to end-stage
disease leading to THA/TKA, and recovery success. This hypothesis will be tested with three specific aims.
Aim 1: To identify genetic variants associated with OA. We will perform GWAS in 292,516 MVP participants
40-80 years of age – of which 90,000 carry an OA diagnosis – in an effort to replicate known and identify new
genetic variants and regions associated with OA. As a secondary analysis, we will perform GWAS to identify
genetic variants associated with OA among 3,696 Veterans with post-traumatic arthritis. We will attempt to
replicate significant findings using data on 392,304 individuals in the UK Biobank, of which 41,217 have OA.
Aim 2: To identify genetic variants prognostic of progression to end-stage OA, as indicated by THA/TKA. We
will perform GWAS in the 90,000 MVP participants with OA to identify variants associated with reaching the
end-stage (i.e. THA/TKA). Within this cohort with diagnosed OA, we will identify genetic variants unique to the
subpopulation that progressed to end-stage – i.e. the 7,600 MVP participants who have undergone THA or
TKA subsequent to OA diagnosis. As a secondary analysis, we will perform GWAS to identify genetic variants
associated with revision surgery within 5 years of the initial THA/TKA, suggesting unique genetic variants that
may predispose some Veterans to poor adaptations to the initial THA/TKA. We will replicate significant findings
using data from 13,071 THA and 12,794 TKA in the UK Biobank. Exploratory Aim: To identify genetic variants
prognostic of THA/TKA recovery defined by mobility limitation (primary outcome), pain, and HRQL (secondary
outcomes). We will perform GWAS among the 7,600 MVP participants with past THA/TKA to identify variants
associated with recovery success or failure, as indicated by MVP Baseline and Lifestyle survey responses. As
a secondary analysis, we will investigate whether rehabilitation mediates the relationship between genetic
variants and THA/TKA recovery. We will maximize heterogeneity using two strategies: (i) By performing GWAS
in each major ethnic group independently and combining results using meta-analysis accounting for trans-
ethnic admixture; and (ii) By analyzing the entire MVP cohort to perform a multi-ethnic GWAS. The ultimate
goal is to identify genetic variants prognostic of OA as well as poor OA and THA/TKA outcomes to develop
targeted, precision pre-habilitation and post-surgical rehabilitation strategies improving mobility function,
HRQL, and healthcare utilization among Veterans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10643606
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Jasvinder A Singh
-
依托单位:
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10839541
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Jasvinder A Singh
-
依托单位:
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10535425
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:10178095
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:9981438
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:10179468
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:9085817
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
SToRytelling to Improve DiseasE outcomes in Gout: The STRIDE-GO Study
-
批准号:8783912
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:10017010
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2012
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:10263207
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2012
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:9767032
-
项目类别:
-
资助金额:$19.57万
-
财政年份:--
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:9370393
-
项目类别:
-
资助金额:$23.0万
-
财政年份:--
-
负责人:Jasvinder A Singh
-
依托单位:
海外基金